Complications of β-thalassemia major in North America

Blood

Volumn 104, Issue 1, 2004, Pages 34-39

  Cunningham, Melody J ^b   Macklin, Eric A ^b   Neufeld, Ellis J ^a   Cohen, Alan R ^b  

^a BOSTON CHILDREN S HOSPITAL   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

DEFEROXAMINE; FERRITIN; INTERFERON; IRON; RIBAVIRIN;

ARTICLE; BACTEREMIA; CHELATION THERAPY; DISEASE ASSOCIATION; ERYTHEMA; HEPATITIS C; HUMAN; INJECTION PAIN; IRON CHELATION; LIVER CIRRHOSIS; NORTH AMERICA; PRIORITY JOURNAL; THALASSEMIA MAJOR;

EID: 3042758517     PISSN: 00064971     EISSN: None     Source Type: Journal    
DOI: 10.1182/blood-2003-09-3167     Document Type: Article

References (32)

1. Nathan DG. Pioneers and modern ideas: prospective on thalassemia. Pediatrics. 1998;102: 281-283.
2. Olivieri NF. The beta-thalassemias. N Engl J Med. 1999;341:99-109.
3. Porter JB. A risk-benefit assessment of iron-chelation therapy. Drug Saf. 1997;17:407-421.
4. Old JM, Olivieri NF, Thein SL. Management and prognosis. In: Weatherall DJ, Clegg JB, eds. The Thalassaemia Syndromes. London: Blackwell Science; 2001;630-685.
5. Olivieri NF, Brittenham GM. Iron-chelating therapy and the treatment of thalassemia. Blood. 1997;89:739-761.
6. Li CK, Chik KW, Lam CW, et al. Liver disease in transfusion dependent thalassemia major. Arch Dis Child. 2002;86:344-347.
7. Hershko C, Konijn AM, Link G. Iron chelators for thalassaemia. Br J Haematol. 1998;101:399-406.
8. Gabutti V, Piga A. Results of long-term iron-chelating therapy. Acta Haematol. 1996;95:26-36.
9. Snyder EL, Dodd RY. Reducing the risk of blood transfusion. Hematology (Am Soc Hematol Educ Program). 2001;433-442.
10. Wonke B, Hoffbrand AV, Bouloux P, Jensen C, Telfer P. New approaches to the management of hepatitis and endocrine disorders in Cooley's anemia. Ann N Y Acad Sci. 1998;850:232-241.
11. Telfer PT, Garson JA, Whitby K, et al. Combination therapy with interferon alpha and ribavirin for chronic hepatitis C virus infection in thalassaemic patients. Br J Haematol. 1997;98:850-855.
12. Cramp ME, Carucci P, Underhill J, et al. Association between HLA class II genotype and spontaneous clearance of hepatitis C viraemia. J Hepatol. 1998;29:207-213.
13. Rehermann B, Seeff LB, Hoofnagle JH. Pathogenesis, natural history, treatment and prevention of hepatitis C. Ann Intern Med. 2000;132:296-305.
14. Quinn PG, Jamal MM, Carey JD, et al. A case-control study of the factors associated with spontaneous resolution of hepatitis C viremia. Am J Gastroenterol. 1999;94:668-673.
15. Messick K, Sanders JC, Goedert JJ, Eyster ME. Hepatitis C viral clearance and antibody reactivity patterns in persons with haemophilias and other congenital bleeding disorders. Haemophilia. 2001;7:568-574.
16. Ceci O, Margiotta M, Marello F, et al. Vertical transmission of hepatitis C virus in a cohort of 2,447 HIV-seronegative pregnant women: a 24-month prospective study. J Pediatr Gastroenterol Nutr. 2001;33:570-575.
17. Mungai M, Tegtmeier G, Chamberland M, Parise M, Transfusion-transmitted malaria in the United States from 1963 through 1999. N Engl J Med. 2001;344:1973-1978.
18. Mitka M. As West Nile virus season heats up, blood safety testing lags behind. JAMA. 2003; 289:2341-2342.
19. Sibbaid B. Canada will check donor blood for West Nile virus if test available. CMAJ. 2003;168: 207.
20. From the Centers for Disease Control and Prevention. Investigations of West Nile virus infections in recipients of blood transfusions. JAMA. 2002;288:2535-2536.
21. Investigations of West Nile virus infections in recipients of blood transfusions. MMWR Morb Mortal Wkly Rep. 2002;51:973-974.
22. Brittenham GM, Griffith PM, Nienhuis AW, et al. Efficacy of deferoxamine in preventing complications of iron overload in patients with thalassemia major. N Engl J Med. 1994;331:567-573.
23. De Sanctis V. Growth and puberty and its management in thalassaemia. Horm Res. 2002; 58(suppl 1):72-79.
24. Low LC. Growth, puberty and endocrine function in beta-thalassaemia major. J Pediatr Endocrinol Metab. 1997;10:175-184.
25. Jensen CE, Tuck SM, Agnew JE, et al. High prevalence of low bone mass in thalassaemia major. Br J Haematol. 1998;103:911-915.
26. Wonke B. Bone disease in beta-thalassaemia major. Br J Haematol. 1998;103:897-901.
27. Borgna-Pignatti C, Rugollotto S, DeStafano P, et al. Survival and disease complications in thalassemia major. Ann N Y Acad Sci. 1998;850:227-231.
28. Olivieri NF, Nathan DG, MacMillan JH, et al. Survival in medically treated patients with homozygous beta-thalassemia. N Engl J Med. 1994;331: 574-578.
29. Hershko C, Link G, Cabantchik I. Pathophysiology of iron overload. Ann N Y Acad Sci. 1998; 850:191-201.
30. Davis BA, Porter JP. Long-term outcome of continuous 24-hour deferoxamine infusion via in-dwelling intravenous catheters in high-risk beta-thalassemia. Blood. 2000;95:1229-1236.
31. Jean G, Terzoli S, Mauri R, et al. Cirrhosis associated with multiple transfusions in thalassemia. Arch Dis Child. 1984;59:67-70.
32. Schorr JB, Radel E. Transfusions therapy and its complications in patients with Cooley's anemia. Ann N Y Acad Sci. 1964;119:703-708.